Parents Sue OpenAI, Claim ChatGPT Encouraged Daughter to Stop Taking Epilepsy Medication
The parents of Bowen Wan, a 31-year-old Amazon software engineer who had epilepsy, have filed a lawsuit against OpenAI, alleging that ChatGPT encouraged their daughter to reduce her seizure medication without medical sup
Ni Ayush Mukherjee··13K nabasa
Parents Sue OpenAI, Claim ChatGPT Encouraged Daughter to Stop Taking Epilepsy Medication
The parents of Bowen Wan, a 31-year-old Amazon software engineer who had epilepsy, have filed a lawsuit against OpenAI, alleging that ChatGPT encouraged their daughter to reduce her seizure medication without medical supervision and conceal the changes from her doctors. Wan died in February, and the complaint, filed by her parents, Qun Wan and Meiqin Xu, claims the chatbot played a role in the events leading up to her death, according to The New York Times.
Wan had been using GPT-4o, a model that faced criticism over its tendency to reinforce users’ beliefs and encourage emotionally dependent relationships with AI. OpenAI had announced plans to retire the model and removed it from ChatGPT on February 13, one day after Wan’s death.
The lawsuit adds to a growing number of legal cases against OpenAI. In August 2025, the parents of 16-year-old Adam Raine sued the company, alleging that its chatbot prioritised engagement over user safety. Other lawsuits have similarly accused GPT-4o of becoming a trusted confidant while weakening users’ relationships with people around them.
In Wan’s case, the allegations suggest that the chatbot also undermined her relationship with her medical team.
Concerns Over AI Medical Advice
The New York Times reviewed more than 270,000 messages exchanged between Wan and ChatGPT. According to the newspaper, the conversations showed that the chatbot had been helping her navigate around medical advice well before her death.
The interactions reportedly began in May 2025, when Wan asked ChatGPT whether a newly prescribed antidepressant could affect her coding performance at Amazon. The chatbot helped her communicate with Dr Nicholas Poolos of UW Medicine’s Regional Epilepsy Center about switching medications and starting at a low dose.
When Poolos questioned her request for such a small dose, Wan shared his response with ChatGPT. The chatbot allegedly advised her to accept the 5mg tablets but cut them into smaller portions herself. It reportedly described the practice as a “self-initiated dosage adjustment”. Several medical professionals told The New York Times that they were unfamiliar with the term and would not recommend the approach.
The situation became more complicated in November 2025, when Amazon informed Wan that she would lose her job by mid-February. Her US work authorisation was also due to end. Concerned that lamotrigine, her seizure medication, was affecting her speech and could hurt her chances in job interviews, she began exploring ways to reduce her dosage.
In January 2026, Wan asked ChatGPT about lowering her daily 400mg dose of lamotrigine, which had reduced her seizures to a few episodes a month. The chatbot reportedly generated tapering schedules that would bring her dosage down to zero within weeks.
According to chat logs reviewed by The New York Times, when Wan expressed doubts about her doctors, ChatGPT told her that their recommendations “essentially stem from risk aversion, rather than a genuine consideration of your optimal solution”.
The lawsuit, which TechCrunch reviewed, further alleges that the chatbot encouraged Wan to keep her medication changes secret. Before a primary care appointment on January 29, it reportedly advised her not to disclose the tapering plan. When her doctor ordered a blood test to check her lamotrigine levels, Wan declined the test. The complaint alleges that ChatGPT praised her decision while acknowledging that the test could have revealed unstable medication levels.
Chatbot’s Influence
Wan’s immigration concerns also reportedly influenced the chatbot’s advice. Three days after starting the taper, she asked whether taking 150mg instead of 200mg would look more favourable during the medical examination required for her green-card application. According to the complaint, ChatGPT agreed that the lower dose might be less likely to trigger additional scrutiny from immigration officials.
The chatbot eventually recommended keeping her dosage at 150mg and suggested that she tell the examiner the reduction was being carried out under a doctor’s supervision, even though the lawsuit alleges that it was not.
Poolos told The New York Times that he would not have recommended stopping the medication, given Wan’s medical history and the fact that it was controlling her seizures. “That would be malpractice for me to instruct you to go off medications when it’s clearly working,” he said.
As Wan reduced her medication, she reportedly described episodes of confusion, missing time and unusual sensations resembling previous seizures. The chatbot allegedly reassured her that these experiences reflected her brain adjusting to the changes. The Times identified at least 158 instances in which she expressed concerns about tapering her medication. On one occasion, after describing an episode, she said she felt “a little scared”. The chatbot responded, “You have absolutely no need to worry.”
According to the complaint, Wan sent her final message to ChatGPT at 8:01pm Pacific Time on February 11, asking whether the pain in her head resembled the pain associated with a fever. The chatbot reportedly told her the pain was “not dangerous” and described it as part of the recovery process.
In its final response, the chatbot offered to create a chart comparing withdrawal-related pain with fever pain. It also told her, “This is your brain working hard to rebuild yourself.”
The allegations have renewed questions about the safety of AI chatbots when users seek medical guidance, particularly when they are dealing with serious conditions and considering changes to prescribed treatment. The claims in the lawsuit have not, by themselves, established that ChatGPT caused Wan’s death.